NVCR - NASDAQ
NovoCure Limited
$16.15
+2.1%NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
At a Glance
Live Snapshotnvcr
Total Current Liabilities
Last Annual Value
223.23M
3-Year CAGR
12%
5-Year CAGR
14%
10-Year CAGR
23%
NovoCure Limited Competitors Analysis of Total Current Liabilities
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
NovoCure Limited NASDAQ:NVCR | 223.23M | 7.6% | 9.4% | 19.7% | |
 Azenta, Inc. NASDAQ:AZTA | 237.67M | 4.1% | -7.2% | 7.1% | |
 BioLife Solutions, Inc. NASDAQ:BLFS | 22.98M | -18.3% | -11.7% | 35.1% | |
 Kestra Medical Technologies, Ltd. NASDAQ:KMTS | 37.98M | 1.1% | 41.9% | N/A | |
 Neogen Corporation NASDAQ:NEOG | 174.01M | 6.2% | 26.6% | 19.8% | |
 Pulse Biosciences, Inc. NASDAQ:PLSE | 7.92M | 5.7% | -1.4% | 22.8% | |
 STAAR Surgical Company NASDAQ:STAA | 68.50M | 1.7% | 7.0% | 12.5% | |
 Teladoc Health, Inc. NYSE:TDOC | 404.74M | -1.3% | 4.1% | 34.4% | |
 Upstream Bio, Inc. NASDAQ:UPB | 10.74M | 18.1% | N/A | N/A |
NovoCure Limited Fair Value Envelope
Related Guides
Continue your NVCR research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.